Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Ex-Tokyo Tech President Yoshinao Mishima Named AMED Chief from April
March 30, 2020
- Social Security Council at Odds over Future CEA Use, but Agrees to Watch Chuikyo Debate
March 27, 2020
- ICH Vancouver Meeting Cancelled due to COVID-19 Pandemic
March 27, 2020
- MHLW to Make Pediatric Medical Database Available to Researchers on Trial Basis
March 26, 2020
- OxyContin’s Chronic Pain Nod Delayed as Distribution System Not Ready
March 26, 2020
- Japan OKs Enhertu, 3 Sakigake Drugs, Beovu, Latuda, and More
March 26, 2020
- MHLW Pharma Bureau Chief Tarumi Tapped to Lead Coronavirus Reponses, Mitsuaki Kamata to Take Over
March 25, 2020
- Drug Pricing Rules to Be Applied to Zolgensma: Chuikyo
March 25, 2020
- Pharma, Healthcare Circle See “Off-Year” Drug Re-Pricing Unrealistic amid Coronavirus Crisis
March 25, 2020
- Product Coverage Is the Biggest Theme for Off-Year Re-Pricing Debate: MHLW Official
March 23, 2020
- Japan’s First Ophthalmology Regenerative Medicine Product Approved: J-TEC
March 23, 2020
- Japan Eases 30-Day Inspection Rules to Expedite Coronavirus Trials
March 23, 2020
- MHLW Issues COVID-19 Treatment Guide
March 19, 2020
- Increase Copay for OTC-Like Drugs under New Mixed-Care Scheme: Professor
March 19, 2020
- 3 Key Antibiotics to Receive Price Raises through Unprofitability Re-Pricing
March 18, 2020
- Japan Grants Orphan Status to 7 Drugs
March 18, 2020
- Japan’s Avigan Stockpile for Some 2 Million People; No Plan for Increase: Govt
March 18, 2020
- Health Minister Reiterates Support for COVID-19 Drug Development; MHLW Accelerating Rollout of Quick Testing
March 18, 2020
- Japan to Launch Panel on Stable Drug Supplies after Cefazolin Woes; Coronavirus Outbreak Possibly Up for Discussion
March 17, 2020
- Revised Special Flu Law Enforced; Japan Can Now Declare Emergency over COVID-19
March 16, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…